Monzr Al Malki

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

David A. Sallman, Monzr Al Malki, Adam S. Asch et al. · Journal of Clinical Oncology · 2020 · 81 citations

Immunology, Aml Patients, Pathology +16

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

David A. Sallman, William B. Donnellan, Adam S. Asch et al. · Journal of Clinical Oncology · 2019 · 62 citations

Immunology, Pharmacotherapy, Immunotherapeutics +19

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

David A. Sallman, Adam Asch, Suman Kambhampati et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 51 citations

Phase 1B, Oncology, Immunology +4

Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia

Karamjeet Sandhu, Sanjeet Dadwal, Dongyun Yang et al. · Biology of Blood and Marrow Transplantation · 2020 · 43 citations · Full text

Hma-ven Therapy, Mixed-phenotype Acute Leukemia, Immunology +17

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Aleksandr Lazaryan, Michelle Dolan, Mei‐Jie Zhang et al. · Haematologica · 2019 · 36 citations · Full text